CTHRepealedLegislation
//
© 2026 Zoe. All rights reserved.
Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2011 (No. PB 87 of 2011)
Start here
Turn the raw legal text into a practical explanation grounded in National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2011 (No. PB 87 of 2011).
20 Maximum number of repeats — paragraph 10 (1) (a) prescription
(1) If a prescription for the supply of a chemotherapy pharmaceutical benefit is written in accordance with paragraph 10 (1) (a), the maximum number of occasions an eligible medical practitioner may, in 1 prescription, direct that the supply of the chemotherapy pharmaceutical benefit be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the chemotherapy pharmaceutical benefit.
(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum number for the particular purposes mentioned in Schedule 3 for each code.
(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum number for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.
(4) If a prescription is written in accordance with paragraph 10 (1) (a) for the repeat supply of a chemotherapy pharmaceutical benefit that is greater than the maximum number of occasions an eligible medical practitioner may, in 1 prescription, direct the repeat supply of a chemotherapy pharmaceutical benefit under this section, the prescription must be authorised in accordance with the procedures mentioned in regulation 13 of the Regulations as modified by subsection (5).
(5) A reference in regulation 13 of the Regulations to a determination in force under paragraph 85A(2)(b) of the Act is to be read as a reference to the maximum number of occasions an eligible medical practitioner may, in one prescription, direct that the supply of the chemotherapy pharmaceutical be repeated as described in this section.
(6) A reference in regulation 24 of the Regulations to a determination in force under paragraph 85A(2)(b) of the Act is to be read as a reference to the maximum number of occasions an eligible medical practitioner may, in one prescription, direct that the supply of the chemotherapy pharmaceutical be repeated as described in this section.
(7) For this section, the chemotherapy pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1: